Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34619574

about

Emerging molecularly targeted therapies in castration refractory prostate cancer SECONDARY HORMONAL MANIPULATIONS IN THE TREATMENT OF CASTRATION REFRACTORY PROSTATE CANCER The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).Metastatic castration-resistant prostate cancer: time for innovation.Cabazitaxel for the treatment of castration-resistant prostate cancer.Emerging treatments for castrate-resistant prostate cancer.

P2860

Q21284745-A00411C0-047B-4B55-96DF-447FDE4CB661 Q29302403-F2EB7680-65AB-4921-A05D-1AD01CD7DA46 Q37235511-17625F67-D825-498B-907A-68EE5AB3A6AB Q37868056-48B208FA-A3AF-495E-AA69-A0B4E2CA70C8 Q38019954-1BEDCC9E-E128-47DE-9FFA-40BF2406D99C Q38312041-950AE163-0A04-483D-BE1A-16397A7D2BD4 Q38861952-8BDEC6E0-71BF-4B0C-8F45-4FD47C17FD86 Q44336766-DA4375A9-3DB1-465F-9F13-96AABED525B6

P2860

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34619574

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@ast

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@en

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@nl

type

label

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@ast

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@en

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@nl

prefLabel

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@ast

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@en

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@nl

P1433

Q34619574-D1345CEC-461B-41BA-9589-54132A20FA48

P1476

Q34619574-F61C3A60-44BF-4F7B-93D7-30BC95235719

P2093

Q34619574-013237B7-1DC9-4B30-8A92-64069FF0C892

Q34619574-19E7CF6F-E1FD-4030-A4F0-EE52BAA51DEA

Q34619574-711A5CD2-BC7C-4D5D-A178-B275BC7A69C6

Q34619574-78FEB41F-0646-49E9-BF23-810C08F9DB1D

P2860

Q34619574-00AC77FB-C3F0-429F-B297-E6E0BEAA8B92

Q34619574-050B7325-795A-4641-B3DE-1B88181FF0BE

Q34619574-1374E9C9-47A3-421F-8957-99B57D4DA55F

Q34619574-1A8240E2-207E-4791-A48E-3FE9942FEC6A

Q34619574-1C5E58DD-FB1D-4C7D-91BC-F7C9D0123FC8

Q34619574-1CCC8223-670B-4BF6-A610-44C28D3AF096

Q34619574-1FD7576E-3A10-4687-B700-9648B98BA41D

Q34619574-370AF8C1-A149-462C-ACF0-B653ED4FA40A

Q34619574-380CB40D-4A54-4E26-A254-7F963C677F11

Q34619574-421E5658-AF3D-44D5-9FCB-A8C78A3B8D51

P304

Q34619574-65986887-7FB9-4B00-AA06-CFDB017AD266

P31

Q34619574-B787DE8F-CDA9-4CC8-A3B8-12B209DD4C71

P356

Q34619574-3431828C-04D0-4BA4-A0C2-798F8E511A18

P407

Q34619574-176AB167-5D63-4CFA-B4E3-EE97897A98EC

P433

Q34619574-FA535F63-BFD0-4CA5-8648-60900922AC71

P478

Q34619574-14956CD8-4FEE-4BDA-81CE-E74A3341D4D9

P577

Q34619574-929883EC-C034-4B46-9B20-C0CE36D226EE

P698

Q34619574-2BE34955-7656-4667-8A71-F7D031AEE0F7

P921

Q34619574-E6D64397-B7AD-4314-B8E4-F71FC684A647

P356

P1433

Future Oncology

P1476

Abiraterone acetate: a promisi ...... ion-resistant prostate cancer.

@en

P2093

Guru Sonpavde

http://www.w3.org/2001/XMLSchema#string

Neeraj Agarwal

http://www.w3.org/2001/XMLSchema#string

Nicholas J Vogelzang

http://www.w3.org/2001/XMLSchema#string

Thomas E Hutson

http://www.w3.org/2001/XMLSchema#string

P2860

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes

Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture

PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

P304

665-679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.10.48

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20465382

http://www.w3.org/2001/XMLSchema#string

P921

abiraterone acetate